Skin care for cancer patients

Clinical Advances in Hematology and Oncology

Volumn 10, Issue 11, 2012, Pages 748-750

  Lacouture, Mario E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIMETABOLITE; BORTEZOMIB; CETUXIMAB; ERLOTINIB; EVEROLIMUS; PANITUMUMAB; SORAFENIB; TEMSIROLIMUS; VEMURAFENIB;

ACNE; ARTICLE; DERMATOLOGIST; HAIR LOSS; HAND FOOT SYNDROME; HUMAN; HUMIDIFIER; MUCOSA INFLAMMATION; NAIL DISEASE; NEOPLASM; PATIENT REFERRAL; RASH; SKIN CARE; SKIN IRRITATION; STEVENS JOHNSON SYNDROME; SUN EXPOSURE; TOXIC EPIDERMAL NECROLYSIS;

ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SKIN DISEASES; TREATMENT OUTCOME;

EID: 84872692250     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Lacouture ME. Dr. Lacouture's Skin Care Guide for People Living With Cancer. Cold Spring Harbor, NY: Harborside Press, LLC; 2012.
2. Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology. 2007;72:152-159.
3. Kinahan KE, Sharp LK, Seidel K, et al. Scarring, disfigurement, and quality of life in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor study. J Clin Oncol. 2012;30:2466-2474.
4. Kinahan KE, Gandhi M, Lacouture ME, et al. Dermatologic issues in adult survivors of childhood cancer. J Cancer Surviv. 2009;3:158-163.
5. Balagula Y, Rosen A, Tan BH, et al. Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. Cancer. 2012;118:5078-5083.
6. Borovicka JH, Calahan C, Gandhi M, et al. Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents. Arch Dermatol. 2011;147:1403-1409.
7. Gomez P, Lacouture ME. Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. Oncologist. 2011;16:1508-1519.
8. Balagula Y, Rosen ST, Lacouture ME. The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies. J Am Acad Dermatol. 2011;65:624-635.
9. Wu PA, Balagula Y, Lacouture ME, Anadkat MJ. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors. Curr Opin Oncol. 2011;23:343-351.
10. Balagula Y, Garbe C, Myskowski PL, et al. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol. 2011;50:129-146.
11. Balagula Y, Lacouture ME, Cotliar JA. Dermatologic toxicities of targeted anticancer therapies. J Support Oncol. 2010;8:149-161.